bipolar I disorder
Mental health · 2008–2018
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aripiprazole Acute and maintenance treatment of schizophrenia in adults; maintenance treatment to prevent recurrence of manic or mixed episodes of bipolar I disorder in… | Jul 2018 | Recommended with restriction | none received |
| quetiapine Maintenance therapy for treatment of acute mania, bipolar I disorder, and schizophrenia. The submission requested change in listing to allow up to 5 repeats… | Mar 2018 | Recommended | no section in document |
| asenapine Treatment of acute mania or mixed episodes associated with bipolar I disorder (as monotherapy or in combination with lithium or sodium valproate) and… | Jul 2011 | Recommended with restriction | unclear |
| quetiapine Maintenance treatment of bipolar I disorder as monotherapy. The submission also requested a broader listing for treatment of bipolar disorder more generally,… | Jul 2010 | Recommended with restriction | no section in document |
| quetiapine Maintenance treatment of bipolar I disorder as monotherapy. The submission also requested a broader listing for treatment of bipolar disorder, but PBAC… | Jul 2010 | Recommended with restriction | no section in document |
| quetiapine fumarate Maintenance treatment of bipolar I disorder, in combination with lithium or sodium valproate, for the prevention of recurrence of manic, depressive or mixed… | Mar 2009 | Recommended with restriction | no section in document |
| ziprasidone hydrochloride Monotherapy, for up to 6 months, of an episode of acute mania or mixed episodes associated with bipolar I disorder. | Nov 2008 | Recommended with restriction | no section in document |
What the PBS pays
$117M in government benefit over 2024–25, across 2,452,495 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| aripiprazole | $72.4M |
| quetiapine | $19.3M |
| quetiapine fumarate | $19.3M |
| asenapine | $3.7M |
| ziprasidone hydrochloride | $2.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| aripiprazoleAripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | recommended | 2013-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.